$ABCL News

AbCellera Biologics Inc. 2026 Q1 - Results - Earnings Call Presentation

AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript

AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate

Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7

AbCellera To Disclose Interim Results From Phase 1 Portion Of Its Study Of ABCL635, Including Observed Safety Profile, Pharmacokinetic, And Pharmacodynamic Target Engagement Data, During Q1 Earnings Call On May 11

Is Jones Trading’s New Coverage of AbCellera (ABCL) Reframing Its Clinical-Stage Platform Narrative?

AbCellera Biologics (ABCL) Committed to Leverage Differentiated Technology for Drug Discovery

Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11

AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera: Dart-Board Approach Reflects Trading Premium (Upgrade)

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says

Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next

AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M

AbCellera Biologics Inc. Q4 2025 Earnings Call Summary

AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges